Currently Viewing:
American Society of Clinical Oncology Annual Meeting
Currently Reading
Persephone Trial: Cutting Trastuzumab Duration by Half Safer, Efficacious in HER2-Positive Breast Cancer
May 29, 2018
Despite USPSTF Recommendations, Lung Screening Rates Low Among Heavy Smokers
May 31, 2018
Nelarabine With Chemotherapy Boosted Outcomes in Pediatric and YA Patients With T-Cell Cancers
June 01, 2018
Dr Leonard B. Saltz on Deciding When a Patient Should Receive NGS Testing
June 02, 2018
Promising Early Phase Results With bb2121 CAR T Treatment in Relapsed Refractory Multiple Myeloma
June 02, 2018
Dr Peter Paul Yu Discusses the Impact of Health Information Technology in Oncology
June 02, 2018
Identifying Rational Immunotherapy Combinations for Glioblastoma: A Progress Report
June 02, 2018
Dr James Lin Chen Outlines Information Needs in Era of Precision Medicine
June 02, 2018
Ellen Miller Sonet Highlights Financial Burdens of Patients With Cancer
June 02, 2018
Utilization Management in Oncology: Current Strategies and a Path Forward
June 02, 2018
Immune Checkpoint Inhibitors Improve Outcomes in Mismatch Repair Deficient CRC, but Can Induce irAEs
June 02, 2018
ZUMA-1: Response to Axi-cel at Three Months Prognostic for Remission in B-cell Lymphoma
June 03, 2018
Cetuximab With Chemoradiation Worse Than Chemoradiation Alone in Older Patients With HNSCC
June 03, 2018
Dr Michael Thompson: The Role of Precision Medicine in the Community Setting
June 03, 2018
Dr Victoria Villaflor Outlines Challenges With Pursuing Precision Medicine
June 03, 2018
Clinical Trials: Sharing the Road With Real-World Evidence
June 04, 2018
Phase 3 TAILORx Results Confirm Chemotherapy Unnecessary in 70% of Women With Early-Stage Breast Cancer
June 04, 2018
KEYNOTE-042 Confirms First-Line Pembrolizumab Superior to Chemotherapy in PD-L1–Low Advanced NSCLC
June 04, 2018
Cemiplimab, in GOG 3016, Looks to Break New Ground for Immunotherapy in Cervical Cancer
June 04, 2018
Nearly Half of Patients With Metastatic CSCC Respond to Cemiplimab, on Fast Track at FDA
June 04, 2018
Opdivo Plus Chemo Boosts Progression-Free Survival 26% Over Chemo Alone in Late-Stage NSCLC
June 04, 2018
Managing Cancer-Related Pain in the Era of the Opioid Crisis
June 06, 2018
Discussing the Cost Burden of Cancer With Patients
June 06, 2018
Study Underscores Value of PROs in Improving Lung Cancer Survival
June 07, 2018

Dr Peter Paul Yu on Progress in the Move Toward Interoperability

Peter Paul Yu, MD, FASCO, FACP, physician-in-chief, Hartford HealthCare Cancer Center, discusses the shift toward interoperability among electronic health record systems and efforts needed to accelerate this shift.


Peter Paul Yu, MD, FASCO, FACP, physician-in-chief, Hartford HealthCare Cancer Center, discusses the shift toward interoperability among electronic health record systems and efforts needed to accelerate this shift.

Transcript

How much progress has there been in the move toward interoperability among EHR systems? What efforts are needed to accelerate the shift?

Most people when they talk about interoperability, they talk about it in the way of how do you get it from one electronic health record (EHR) into the other EHR, and that’s relevant, if the patient is moving from Seattle to Kansas City and you need to move records across, and it’s relevant if you were in a cardiologist's office yesterday and today you’re seeing the orthopedic doctor and you need to move it around. That’s generally what people talk about in terms of interoperability.

From an oncologist point of view, I think it’s somewhat different. From an oncologist point of view, I think it’s more about: how do you get the data that’s in an electronic health record connected to the data that’s in the radiation oncologist’s record, which is driving the Linux, and how do you get it connected to the pathology office, which has their detailed pathology report information? How do you move that into the cancer registry, so you can satisfy your reporting requirements? For oncology, it’s not so much about moving it from one EHR to another EHR, its more about how do we aggregate the whole sum of the patient’s cancer experience in a database?

Having defined that, the bad news is that there’s very little going on there because when you’re talking about one EHR to another EHR, there is a basic data set that’s in common to all your charge. The representation and how its captured is different, but the data is, in theory, similar, and you can move it around. And when you take it out of one EHR, you can dump it into another spot, another EHR. When you’re talking about moving things like genomic data from a precision medicine next-generation sequencing test and you have 500 mutations to report on and there’s not a single landing field for each of those mutations in the EHR, now you have a really big problem. So, I think this is an area that we’ve just started the discussion and awareness of, but I’d say right now we’re far from even recognizing the importance of this need.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up